However, the S1 subunit containing the RBD is likely to stimulate the majority of neutralizing antibodies in COVID-19 patients and almost all the highly potent neutralizing monoclonal antibodies isolated from COVID-19 convalescent patients were found to bind to the S1 subunit [39,40]. Here, PSMD1 is linked to COVID-19.